Sining Xie, Federica Galimberti, Elena Olmastroni, Alberico L. Catapano, Manuela Casula
Dear Editor,
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Although several therapeutic options are available to reduce LDL-cholesterol (LDL-C), many patients continue to experience major cardiovascular (CV) events. In ASCVD, inflammation plays a critical role, contributing significantly to residual CV risk [1]. Several anti-inflammatory therapies have been evaluated to reduce CV risk, and recently, the U.S. Food and Drug Administration approved the use of low-dose colchicine to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, or CV death in adult patients with established ASCVD or multiple CV risk factors [2, 3]. Meta-analyses have shown that low-dose colchicine (0.5–1.0 mg) can lead to a reduction in C-reactive protein (CRP) levels by −0.36 mg/L (95%CI, −0.51 to −0.20) in patients with coronary artery disease [4, 5], and by −0.66 mg/L (95%CI, −0.98 to −0.35) in patients with acute MI [6], which translates into a 35% and 44% reduction in major CV events, respectively. Nevertheless, some studies have suggested an anti-inflammatory effect with some lipid-lowering therapies. In a recent meta-analysis involving 171,668 subjects from 53 randomized control trials (RCTs), we demonstrated a reduction in serum CRP concentration with statins (−0.65 mg/L [95%CI, −0.87 to −0.43]), bempedoic acid (−0.43 mg/L [95%CI, −0.67 to −0.20]), and ezetimibe (−0.28 mg/L [95%CI, −0.48 to −0.08]), which was independent of LDL-C changes [7].
Given the growing interest in targeting inflammation to further reduce CV risk and the recent inclusion of colchicine among CV preventive therapies [8], it appears of interest to compare the effect of available therapies on plasma CRP levels. Therefore, we sought to quantify the additional effect of adding colchicine to statins on CRP levels and to compare the effect of bempedoic acid, ezetimibe, or colchicine added to background statin treatment.
Because no trial directly compares the impact on CRP levels of colchicine versus lipid-lowering therapies, we performed a network meta-analysis according to the PRISMA guidelines. PubMed, Web of Science, EMBASE, Cochrane Library, and ClinicalTrial.gov were searched from inception to November 2023. Inclusion criteria were as follows: (1) RCTs in human, parallel design, phase II, III, or IV; (2) English language; (3) using ezetimibe, bempedoic acid, or colchicine as interventions on top of statin treatment (defined as more than 80% patients treated with statins at baseline); (4) reporting the effect on CRP levels; (5) with an intervention duration of more than 3 weeks.
Pooled estimates were assessed by both fixed-effect and random-effects models within a Bayesian hierarchical setting, assuming equal heterogeneity across all comparisons. When significant heterogeneity was detected (as determine
{"title":"Effect on C-reactive protein levels of the addition of ezetimibe, bempedoic acid, or colchicine to statin treatment: A network meta-analysis","authors":"Sining Xie, Federica Galimberti, Elena Olmastroni, Alberico L. Catapano, Manuela Casula","doi":"10.1111/joim.13824","DOIUrl":"10.1111/joim.13824","url":null,"abstract":"<p>Dear Editor,</p><p>Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Although several therapeutic options are available to reduce LDL-cholesterol (LDL-C), many patients continue to experience major cardiovascular (CV) events. In ASCVD, inflammation plays a critical role, contributing significantly to residual CV risk [<span>1</span>]. Several anti-inflammatory therapies have been evaluated to reduce CV risk, and recently, the U.S. Food and Drug Administration approved the use of low-dose colchicine to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, or CV death in adult patients with established ASCVD or multiple CV risk factors [<span>2, 3</span>]. Meta-analyses have shown that low-dose colchicine (0.5–1.0 mg) can lead to a reduction in C-reactive protein (CRP) levels by −0.36 mg/L (95%CI, −0.51 to −0.20) in patients with coronary artery disease [<span>4, 5</span>], and by −0.66 mg/L (95%CI, −0.98 to −0.35) in patients with acute MI [<span>6</span>], which translates into a 35% and 44% reduction in major CV events, respectively. Nevertheless, some studies have suggested an anti-inflammatory effect with some lipid-lowering therapies. In a recent meta-analysis involving 171,668 subjects from 53 randomized control trials (RCTs), we demonstrated a reduction in serum CRP concentration with statins (−0.65 mg/L [95%CI, −0.87 to −0.43]), bempedoic acid (−0.43 mg/L [95%CI, −0.67 to −0.20]), and ezetimibe (−0.28 mg/L [95%CI, −0.48 to −0.08]), which was independent of LDL-C changes [<span>7</span>].</p><p>Given the growing interest in targeting inflammation to further reduce CV risk and the recent inclusion of colchicine among CV preventive therapies [<span>8</span>], it appears of interest to compare the effect of available therapies on plasma CRP levels. Therefore, we sought to quantify the additional effect of adding colchicine to statins on CRP levels and to compare the effect of bempedoic acid, ezetimibe, or colchicine added to background statin treatment.</p><p>Because no trial directly compares the impact on CRP levels of colchicine versus lipid-lowering therapies, we performed a network meta-analysis according to the PRISMA guidelines. PubMed, Web of Science, EMBASE, Cochrane Library, and ClinicalTrial.gov were searched from inception to November 2023. Inclusion criteria were as follows: (1) RCTs in human, parallel design, phase II, III, or IV; (2) English language; (3) using ezetimibe, bempedoic acid, or colchicine as interventions on top of statin treatment (defined as more than 80% patients treated with statins at baseline); (4) reporting the effect on CRP levels; (5) with an intervention duration of more than 3 weeks.</p><p>Pooled estimates were assessed by both fixed-effect and random-effects models within a Bayesian hierarchical setting, assuming equal heterogeneity across all comparisons. When significant heterogeneity was detected (as determine","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":9.0,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13824","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nada Maaziz, Laurent Martin, Alexandre Marchand, Betty Gardie, François Girodon
Dear Editor,
The upcoming Olympic Games will be accompanied by intense testing for doping, which is unfortunately not uncommon in top-level sporting circles. Among classic doping products used in endurance sports, erythropoietin (EPO) drug, the biological copy of the main EPO hormone responsible for substantial increases in haemoglobin (Hb) concentration and haematocrit (Ht), is one of the originals, both in terms of its age (available since the 1980s) and frequency of use (61 doping cases worldwide in 2022) [1].
The history of the Olympic Games is associated with the discovery of mutations in the EPO receptor gene, EPOR, in the 1990s. The first mutation was identified in Eero Mäntyranta, who won multiple Olympic and world champion medals in cross-country skiing [2]. At that time, no technique was available to identify blood doping using EPO drug, or transfusion, for which methods were validated in the early 2000s [3].
Here, we report two cases in which top-level athletes were disqualified solely on the basis of high Hb and Ht values. These athletes were found to be carriers of familial polycythaemia associated with functionally tested pathogenic mutations in genes involved in the hypoxia-sensing pathway several years after their disqualification from the sporting world, underlining the importance of having recourse to specialized testing before making serious accusations.
A 34-year-old male, who started playing soccer at a young age, applied to enter a sports-study high school when he was 16 years old. His application was rejected due to the presence of high Hb and Ht values (Table 1). The doctor overseeing his case suspected doping, leading to the man's subsequent ban from sports study in high school and competitions. Eighteen years later, his son was diagnosed with polycythaemia, suggesting familial erythrocytosis and samples from the father and son were analysed using NGS sequencing with a gene panel dedicated to the exploration of polycythaemia. A pathogenic mutation (p.Asp525Gly) in EPAS1 was identified in the father and son and three other relatives segregating with a polycythaemia phenotype. The EPAS1 gene encodes the hypoxia-inducible factor HIF2α, which regulates the expression of EPO when oxygen concentrations go down.
The second medical record concerns a top-level national Taekwondo athlete, for whom a routine examination revealed high Ht and Hb values (Table 1), leading to definitive banishment from competition. Ten years later, the patient's sister was referred to the hospital for absolute idiopathic polycythaemia. Given the sister's history of polycythaemia, the hypoxia-regulating genes were sequenced, which revealed a pathogenic mutation in the EGLN1 gene (p.Trp334Arg). EGLN1 encodes the PHD2 protein, which plays a major role in the degradation of HIF2α. This mutation was found in the athlete and her sister, as well as in thr
{"title":"Olympic Games: When the haematocrit does not fit, the athlete is not always a cheat","authors":"Nada Maaziz, Laurent Martin, Alexandre Marchand, Betty Gardie, François Girodon","doi":"10.1111/joim.13822","DOIUrl":"10.1111/joim.13822","url":null,"abstract":"<p>Dear Editor,</p><p>The upcoming Olympic Games will be accompanied by intense testing for doping, which is unfortunately not uncommon in top-level sporting circles. Among classic doping products used in endurance sports, erythropoietin (EPO) drug, the biological copy of the main EPO hormone responsible for substantial increases in haemoglobin (Hb) concentration and haematocrit (Ht), is one of the originals, both in terms of its age (available since the 1980s) and frequency of use (61 doping cases worldwide in 2022) [<span>1</span>].</p><p>The history of the Olympic Games is associated with the discovery of mutations in the EPO receptor gene, <i>EPOR</i>, in the 1990s. The first mutation was identified in Eero Mäntyranta, who won multiple Olympic and world champion medals in cross-country skiing [<span>2</span>]. At that time, no technique was available to identify blood doping using EPO drug, or transfusion, for which methods were validated in the early 2000s [<span>3</span>].</p><p>Here, we report two cases in which top-level athletes were disqualified solely on the basis of high Hb and Ht values. These athletes were found to be carriers of familial polycythaemia associated with functionally tested pathogenic mutations in genes involved in the hypoxia-sensing pathway several years after their disqualification from the sporting world, underlining the importance of having recourse to specialized testing before making serious accusations.</p><p>A 34-year-old male, who started playing soccer at a young age, applied to enter a sports-study high school when he was 16 years old. His application was rejected due to the presence of high Hb and Ht values (Table 1). The doctor overseeing his case suspected doping, leading to the man's subsequent ban from sports study in high school and competitions. Eighteen years later, his son was diagnosed with polycythaemia, suggesting familial erythrocytosis and samples from the father and son were analysed using NGS sequencing with a gene panel dedicated to the exploration of polycythaemia. A pathogenic mutation (p.Asp525Gly) in <i>EPAS1</i> was identified in the father and son and three other relatives segregating with a polycythaemia phenotype. The <i>EPAS1</i> gene encodes the hypoxia-inducible factor HIF2α, which regulates the expression of EPO when oxygen concentrations go down.</p><p>The second medical record concerns a top-level national Taekwondo athlete, for whom a routine examination revealed high Ht and Hb values (Table 1), leading to definitive banishment from competition. Ten years later, the patient's sister was referred to the hospital for absolute idiopathic polycythaemia. Given the sister's history of polycythaemia, the hypoxia-regulating genes were sequenced, which revealed a pathogenic mutation in the <i>EGLN1</i> gene (p.Trp334Arg). <i>EGLN1</i> encodes the PHD2 protein, which plays a major role in the degradation of HIF2α. This mutation was found in the athlete and her sister, as well as in thr","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":9.0,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13822","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141562198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ann Bugeja, Celine Girard, Manish M Sood, Claire E Kendall, Ally Sweet, Ria Singla, Pouya Motazedian, Amanda J Vinson, Marcel Ruzicka, Gregory L. Hundemer, Greg Knoll, Daniel I McIsaac